OBJECTIVES: To study the efficacy of hematopoietic stem cell transplantation (HCT) for ameliorating the clinical manifestations of alpha-mannosidosis. STUDY DESIGN: Four patients with alpha-mannosidosis underwent allogeneic HCT at the University of Minnesota. Diagnosis was established by assay of leukocyte alpha-mannosidase activity level. Physical features, donor engraftment, leukocyte alpha-mannosidase activity, neuropsychologic function, and hearing were monitored before and after transplantation, with follow-up ranging from 1 to 6 years. RESULTS: All 4 patients showed slowing of their neurocognitive development and sensorineural hearing loss before HCT. All patients are alive, with normalization of leukocyte enzyme activity after HCT. Intellectual function has stabilized, with improvement in adaptive skills and verbal memory function in 3 of 4 patients. Hearing has improved to normal or near normal for speech frequencies in 3 patients. No new skeletal abnormalities have developed. CONCLUSIONS: HCT can halt the progressive cognitive loss in patients with alpha-mannosidosis. Early diagnosis and treatment with HCT is critical for optimal results.
OBJECTIVES: To study the efficacy of hematopoietic stem cell transplantation (HCT) for ameliorating the clinical manifestations of alpha-mannosidosis. STUDY DESIGN: Four patients with alpha-mannosidosis underwent allogeneic HCT at the University of Minnesota. Diagnosis was established by assay of leukocyte alpha-mannosidase activity level. Physical features, donor engraftment, leukocyte alpha-mannosidase activity, neuropsychologic function, and hearing were monitored before and after transplantation, with follow-up ranging from 1 to 6 years. RESULTS: All 4 patients showed slowing of their neurocognitive development and sensorineural hearing loss before HCT. All patients are alive, with normalization of leukocyte enzyme activity after HCT. Intellectual function has stabilized, with improvement in adaptive skills and verbal memory function in 3 of 4 patients. Hearing has improved to normal or near normal for speech frequencies in 3 patients. No new skeletal abnormalities have developed. CONCLUSIONS: HCT can halt the progressive cognitive loss in patients with alpha-mannosidosis. Early diagnosis and treatment with HCT is critical for optimal results.
Authors: Stacey B Gabriel; Joseph G Gleeson; Tracy J Dixon-Salazar; Jennifer L Silhavy; Nitin Udpa; Jana Schroth; Stephanie Bielas; Ashleigh E Schaffer; Jesus Olvera; Vineet Bafna; Maha S Zaki; Ghada H Abdel-Salam; Lobna A Mansour; Laila Selim; Sawsan Abdel-Hadi; Naima Marzouki; Tawfeg Ben-Omran; Nouriya A Al-Saana; F Müjgan Sonmez; Figen Celep; Matloob Azam; Kiley J Hill; Adrienne Collazo; Ali G Fenstermaker; Gaia Novarino; Naiara Akizu; Kiran V Garimella; Carrie Sougnez; Carsten Russ Journal: Sci Transl Med Date: 2012-06-13 Impact factor: 17.956
Authors: Janis L Abkowitz; Kathleen M Sabo; Zhantao Yang; Charles H Vite; Laurence E Shields; Mark E Haskins Journal: Transplantation Date: 2009-08-15 Impact factor: 4.939